An interesting case. Not least that it ends up with self-administration of subcutaneous injections. After all, we see B12 patients being told they cannot self-administer because the B12 products are only licensed for intramuscular administration. And the current Serb injectable levothyroxine says intramuscular or intravenous. But not subcutaneous.
If you at all interested, it is strongly recommended that you read the full paper - which is well-written and easy to follow.
Intramuscular and Subcutaneous Levothyroxine: Success in Treating Refractory Hypothyroidism
Eur Thyroid J. 2025 Mar 1:ETJ-25-0012. doi: 10.1530/ETJ-25-0012. Online ahead of print.
Authors
Nadia Chaudhury 1 , Winston Crasto 2 , Ponnusamy Saravanan 3 , Vinod Patel 4
1 N Chaudhury, Department of Diabetes and Endocrinology, George Eliot Hospital NHS Trust, Nuneaton, CV10 7DJ, United Kingdom of Great Britain and Northern Ireland.
2 W Crasto, George Eliot Hospital NHS Trust, Nuneaton, United Kingdom of Great Britain and Northern Ireland.
3 P Saravanan, University of Warwick Medical School, Coventry, United Kingdom of Great Britain and Northern Ireland.
4 V Patel, University of Warwick Medical School, Coventry, United Kingdom of Great Britain and Northern Ireland.
PMID: 40163437
DOI: 10.1530/ETJ-25-0012
Abstract
Introduction:
Refractory hypothyroidism often poses a clinical problem as treatment regimens are difficult to individualise to the patient and feasibility of its delivery is difficult to organise within a health care system. We present a patient who became intolerant of intramuscular (IM) levothyroxine (LT4) after 18 years of treatment, thus subcutaneous (SC) LT4 was initiated.
Case presentation:
13-year-old female with newly-diagnosed hypothyroidism, remained hypothyroid despite escalating doses of oral LT4 and LT3. Thyroxine malabsorption was further suggested by nasogastric administration of LT4, whereby high dose thyroxine administration resulted in only 2.8 pmol/L increase in free T4 level (normal >5.14pmol/L). She eventually achieved long-term euthyroid status at age of 18 with fortnightly IM LT4, alongside oral LT4 and LT3. This was maintained for 18 years. Unfortunately, scar tissue developed around injection sites, resulting in increased pain and difficulty of administration. SC LT4 was trialled with success, and she has remained euthyroid for the last six years with self-administration and minimal side effects.
Conclusion:
Refractory hypothyroidism often presents a challenge for clinicians, both for diagnosis and management. We discuss a patient with longest follow-up to-date within the published literature for both IM and SC LT4 for patient-administered treatment of refractory hypothyroidism and review the literature on alternative formulations available.
PubMed index link here:
https://pubmed.ncbi.nlm.nih.gov/40163437/
Full paper accessible here:
https://etj.bioscientifica.com/view/journals/etj/aop/etj-25-0012/etj-25-0012.xml
